SRC and glioblastoma: Although so far, the results from clinical trials with the Src inhibitor, Dasatinib, have been discouraging, most evidence suggests that more specific Src inhibitors with a higher ability to cross the blood–brain barrier are required to improve glioblastoma therapy [54,55].